Detalhe da pesquisa
1.
Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥â¯60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023.
Euro Surveill
; 29(3)2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38240061
2.
COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022.
Euro Surveill
; 29(13)2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38551095
3.
Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024.
Euro Surveill
; 29(8)2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38390651
4.
I-MOVE multicentre case-control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination?
Euro Surveill
; 21(16)2016 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-27124420
5.
Comparative analysis of health status and health service utilization patterns among rural and urban elderly populations in Hungary: a study on the challenges of unhealthy aging.
Geroscience
; 46(2): 2017-2031, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37798385
6.
Exploring the effect of clinical case definitions on influenza vaccine effectiveness estimation at primary care level: Results from the end-of-season 2022-23 VEBIS multicentre study in Europe.
Vaccine
; 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38704257
7.
Vaccine effectiveness against influenza hospitalisation in adults during the 2022/2023 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network.
Influenza Other Respir Viruses
; 18(2): e13255, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38403302
8.
Influenza vaccine effectiveness in Europe: Results from the 2022-2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study.
Influenza Other Respir Viruses
; 18(1): e13243, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38204584
9.
Real-Time Monitoring of the Effectiveness of Six COVID-19 Vaccines against Laboratory-Confirmed COVID-19 in Hungary in 2021 Using the Screening Method.
Vaccines (Basel)
; 10(11)2022 Oct 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-36366334
10.
Characteristics of the Third COVID-19 Pandemic Wave with Special Focus on Socioeconomic Inequalities in Morbidity, Mortality and the Uptake of COVID-19 Vaccination in Hungary.
J Pers Med
; 12(3)2022 Mar 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35330387
11.
Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study.
PLoS Med
; 8(1): e1000388, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21379316
12.
Unequal burden of COVID-19 in Hungary: a geographical and socioeconomic analysis of the second wave of the pandemic.
BMJ Glob Health
; 6(9)2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34518205
13.
Modeling costs and benefits of the organized colorectal cancer screening programme and its potential future improvements in Hungary.
J Med Screen
; 28(3): 268-276, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33153369
14.
Early Phase of the COVID-19 Outbreak in Hungary and Post-Lockdown Scenarios.
Viruses
; 12(7)2020 06 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-32629880
15.
I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe.
PLoS One
; 6(11): e27622, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-22110695